Melanosis
Conditions
Brief summary
Kligman's trio remains the gold standard treatment for melasma. It contain hydroquinone which is an effective anti-melanogenic compound but that has poor tolerance and numerous side-effects. Thiamidol has been proven to be at least as effective as hydroquinone and has a very good safety profile. The objective of this study is to compare the Kligman's trio to the same preparation in which hydroquinone is replaced by thiamidol.
Interventions
DRUGNew trio de Kligman
Once daily application in addition to the same sunscreen
DRUGTrio Kligman
Once daily application in addition to the same sunscreen
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* SIGNED WRITTEN CONSENT 1) Melasma clinically diagnosed
Exclusion criteria
1. Pregnant woman 2. Other pigmentary disorder affecting the face 3. Use of systemic or topical steroids or retinoids, use of topical depigmenting agents or depigmenting procedure in the month before the inclusion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The melasma's type | at 12 weeks | Clinical score MASI |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the Quality of life of patient | at 12 weeks | descriptive name of scale : meslascol |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORThierry Passeron, PhD
CHU de Nice, Service de Dermatologie
Outcome results
None listed